AstraZeneca/Bristol's Diabetes Drug Priced On Par With First-In-Class Januvia
This article was originally published in The Pink Sheet Daily
Docs may find it tough to tell apart up-and-coming Onglyza and Merck's first-in-class blockbuster Januvia.
You may also be interested in...
AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.